Deck 29: Systemic Lupus Erythematosus

Question 1

One of the most potent inducers of abnormalities and clinical manifestations of SLE is:

A) hydralazine.
B) procainamide.
C) isoniazid.
D) both a and b

Answer 1

both a and b

Question 2

MATCHING
Match the interpretation of the ANA staining pattern to its respective antibody.

Peripheral or rim

A)4-6S RNP
B)Antibody to nucleolar RNA
C)Antibody to any extractable nuclear antigen devoid of DNA or histone
D)nDNA

Answer 2

4-6S RNP

Question 3

The most common form of lupus is:

A) discoid.
B) systemic.
C) drug-induced.

Answer 3

systemic.

Question 4

Many of the clinical manifestations of systemic lupus erythematosus are a consequence of:

A) tissue damage mediated by immune complexes.
B) thrombocytopenia.
C) antiphospholipid syndrome.
D) antibodies to cell surface molecules.

Question 5

A speckled pattern in antinuclear antibody (ANA)testing characterizes:

A) dsDNA,histones,and DNA-histone complexes.
B) anti-RNP and anti-Sm.
C) centromere proteins A,B,and C.
D) nuclear lamins A,B,and C and nuclear pore proteins.

Question 6

A major cellular immunologic feature of SLE is:

A) lack of generalized suppressor T cell function.
B) reduction of generalized suppressor T cell function.
C) hyperproduction of helper T cells.
D) all of the above.

Question 7

The overall incidence of SLE has an increased frequency among:

A) African Americans.
B) Native Americans.
C) Puerto Ricans.
D) all of the above.

Question 8

In SLE,B lymphocytes exhibit:

A) hyperactivity.
B) uncontrolled production of antibodies.
C) suppression of T cell activity.
D) both a and b

Question 9

SLE is more common in:

A) female infants.
B) male infants.
C) adult women.
D) adult men.

Question 10

A condition called the _________________ syndrome can be secondary to lupus and may complicate pregnancy.

A) antiphospholipid
B) antinuclear antibody
C) immune complex
D) plasma cell

Question 11

The site of deposition of immune complexes in systemic lupus erythematosus (SLE)is determined by:

A) molecular configuration.
B) immunoglobulin class.
C) complement-fixing ability.
D) all of the above.

Question 12

A diffused or homogeneous pattern in antinuclear antibody (ANA)testing characterizes:

A) nDNA,ds-DNA,histones,ssDNA,DNP,or histones.
B) Sm,RNP,SS-A,SS-B,hnRNP,and others.
C) centromere proteins A,B,and C.
D) nuclear lamins A,B,and C and nuclear pore proteins.

Question 13

Patients with SLE characteristically manifest:

A) a photosensitive facial rash.
B) polyarthritis.
C) dermatitis.
D) all of the above.

Question 14

Laboratory features of SLE include:

A) the presence of ANAs.
B) circulating anticoagulant and immune complexes.
C) decreased levels of complement.
D) all of the above.

Question 15

Patients with systemic lupus erythematosus exhibit serum antibodies that include:

A) nuclear components.
B) cell surface and cytoplasmic antigens.
C) immunoglobulin G (IgG).
D) all of the above.

Question 16

The most frequent cause(s)of mortality in hospitalized patients with SLE and progressive renal involvement or CNS disease is (are):

A) infection
B) anemia
C) secondary malignancy
D) both a and b

Question 17

Antibodies directed against ___________ cells,including the membrane molecules that mediate their responses,are regularly detected in patients with SLE.

A) T
B) B
C) plasma
D) macrophage

Question 18

MATCHING
Match the interpretation of the ANA staining pattern to its respective antibody.

Nucleolar

A)4-6S RNP
B)Antibody to nucleolar RNA
C)Antibody to any extractable nuclear antigen devoid of DNA or histone
D)nDNA

Question 19

Serologic assessment of renal disease in systemic lupus erythematosus (SLE)includes:

A) cryoglobulin level assay.
B) serum electrophoresis.
C) serum creatinine level assay.
D) urinary protein excretion.

Question 20

Which autoimmune disorder is indicated by an increased titer of anti-Sm (anti-Smith)antibody?

A) Rheumatoid arthritis
B) Systemic lupus erythematosus
C) Progressive systemic sclerosis
D) Polymyositis

Question 21

Fill in the blanks in the table.
Antibodies in Systemic Rheumatic Diseases

A)Anti-native DNA
B)Anti-Jo-1
C)Anti-Scl-1